News Earnings PI Industries Q3FY26 Results: Revenue Declines 28% YoY to ₹13,757 Million, Declares ₹5 Interim DividendPI Industries Q3FY26 Results: Revenue Declines 28% YoY to ₹13,757 Million, Declares ₹5 Interim Dividend
PI Industries reported Q3FY26 consolidated revenue of ₹13,757 million, declining 28% year-on-year from ₹19,008 million. Net profit decreased to ₹3,113 million from ₹3,727 million in Q3FY25. The company declared an interim dividend of ₹5 per share with record date February 23, 2026. Results included exceptional gains of ₹1,051 million primarily from contingent consideration write-back.
*this image is generated using AI for illustrative purposes only.
PI Industries Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, revealing a mixed performance with revenue decline but improved profitability. The agrochemicals major's Board of Directors approved the results at their meeting held on February 12, 2026.
Financial Performance Overview
The company's consolidated revenue from operations declined significantly during the quarter, reflecting challenging market conditions. On a nine-month basis, the performance showed similar trends with revenue compression across key business segments.
| Metric | Q3FY26 | Q3FY25 | Change (%) | 9M FY26 | 9M FY25 | Change (%) |
|---|---|---|---|---|---|---|
| Revenue from Operations | ₹13,757 Mn | ₹19,008 Mn | -27.6% | ₹51,485 Mn | ₹61,907 Mn | -16.8% |
| Total Income | ₹14,424 Mn | ₹19,767 Mn | -27.0% | ₹53,836 Mn | ₹64,615 Mn | -16.7% |
| Net Profit | ₹3,113 Mn | ₹3,727 Mn | -16.5% | ₹11,206 Mn | ₹13,297 Mn | -15.7% |
| Basic EPS | ₹20.52 | ₹24.55 | -16.4% | ₹73.87 | ₹87.65 | -15.7% |
Segment-wise Performance
The company operates through two primary business segments, with agrochemicals contributing the majority of revenues. The pharma segment continued to face headwinds during the reporting period.
Agrochemicals Segment
- Q3FY26 revenue: ₹13,178 million vs ₹18,381 million in Q3FY25
- Nine months revenue: ₹49,556 million vs ₹60,619 million in 9M FY25
- Segment profit before tax: ₹2,879 million in Q3FY26 vs ₹5,366 million in Q3FY25
Pharma Segment
- Q3FY26 revenue: ₹599 million vs ₹637 million in Q3FY25
- Nine months revenue: ₹1,957 million vs ₹1,301 million in 9M FY25
- Segment recorded profit of ₹580 million in Q3FY26 compared to loss of ₹703 million in Q3FY25
Exceptional Items Impact
The quarter's results were significantly influenced by exceptional items totaling ₹1,051 million gain. This included a write-back of contingent consideration of ₹1,260 million related to acquisitions made by subsidiary PI Health Sciences Limited, partially offset by additional employee benefit obligations of ₹209 million due to new labour codes effective from November 21, 2025.
Dividend Declaration
The Board of Directors declared an interim dividend demonstrating confidence in the company's financial position despite revenue challenges.
| Parameter | Details |
|---|---|
| Dividend Rate | ₹5.00 per equity share |
| Face Value | ₹1.00 per share |
| Dividend Percentage | 500% |
| Record Date | February 23, 2026 |
| Payment Date | On or before March 13, 2026 |
Standalone vs Consolidated Performance
On a standalone basis, the company reported revenue from operations of ₹12,696 million in Q3FY26 compared to ₹17,798 million in Q3FY25. Standalone net profit stood at ₹2,816 million versus ₹4,238 million in the corresponding quarter last year. The nine-month standalone revenue was ₹47,913 million against ₹59,230 million in the previous year.
The financial results were reviewed by the Audit Committee and approved by the Board of Directors. Price Waterhouse Chartered Accountants LLP conducted the limited review of both standalone and consolidated financial results, providing unmodified conclusions on the financial statements.
Historical Stock Returns for PI Industries
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.79% | +2.10% | +0.65% | -16.38% | -5.77% | +44.61% |
15
